Sopharma (BGSFA)

Currency in EUR
1.890
+0.040(+2.16%)
Delayed Data·
BGSFA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.8901.895
52 wk Range
1.4102.900
Key Statistics
Bid/Ask
3.94 / 3.99
Prev. Close
5.8
Open
1.89
Day's Range
1.89-1.895
52 wk Range
1.41-2.9
Volume
2.68K
Average Volume (3m)
185.04K
1-Year Change
-24.0964%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BGSFA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Sopharma News & Analysis

Show more

Earnings

Latest Release
May 29, 2026
EPS / Forecast
0.06 / --
Revenue / Forecast
704.57M / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.45%
Dividend Yield
1.67%
Industry Median 1.40%
Annualized payout
0.10
Paid annually
5-Years Growth
+25.67%
Growth Streak

BGSFA Income Statement

Compare BGSFA to Peers and Sector

Metrics to compare
BGSFA
Peers
Sector
Relationship
P/E Ratio
12.4x21.2x−0.4x
PEG Ratio
0.070.360.00
Price/Book
1.9x4.8x2.6x
Price / LTM Sales
0.7x3.9x3.0x
Upside (Analyst Target)
-12.7%54.6%
Fair Value Upside
Unlock6.9%9.7%Unlock

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; veterinary vaccines; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal and cosmetic products, including plasters, bandages, herbal cosmetics, and sanitary-hygiene products; and yophilic products, ointments, syrups, drops, suppositories, inhalers, haemodialysis concentrates, sachets, substances, infusion solutions, veterinary vaccines, solutions and chemical substances and mixture. In addition, the company distributes pharmaceuticals, and sanitary and hygiene products; and provides contract manufacturing services, regulatory services, laboratory analysis, transport services, and other services. Further, it is involved in trading of pharmaceuticals; manufacturing medical plant; and provision of public opinion research services. Additionally, the company engages in the offline and online retail trade of medicinal products and medical equipment; and rental of properties, as well as in trading, consulting, and other activities. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.53M0.29%2.89M
Other Institutional Investors
307.16M58.13%582.06M
Public Companies & Retail Investors
219.75M41.59%416.43M
Total
528.43M100.00%1B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Donev investments holding AD41.07%217,010,935411,236
Telekomplekt Invest AD17.06%90,147,151170,829

FAQ

What Is the Sopharma AD (BGSFA) Stock Price Today?

The Sopharma AD stock price today is 1.890 EUR.

What Stock Exchange Does Sopharma AD Trade On?

Sopharma AD is listed and trades on the Sofia Stock Exchange.

What Is the Stock Symbol for Sopharma AD?

The stock symbol for Sopharma AD is "BGSFA."

Does Sopharma AD Pay Dividends? What’s The Current Dividend Yield?

The Sopharma AD dividend yield is 1.67%.

What Is the Sopharma AD Market Cap?

As of today, Sopharma AD market cap is 998.740M EUR.

What Is Sopharma AD's Earnings Per Share (TTM)?

The Sopharma AD EPS (TTM) is 0.450.

When Is the Next Sopharma AD Earnings Date?

Sopharma AD will release its next earnings report on Mar 04, 2026.

From a Technical Analysis Perspective, Is BGSFA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sopharma AD Stock Split?

Sopharma AD has split 2 times.

How Many Employees Does Sopharma AD Have?

Sopharma AD has 6005 employees.

What is the current trading status of Sopharma AD (BGSFA)?

As of Jul 21, 2026, Sopharma AD (BGSFA) is trading at a price of 1.890 EUR, with a previous close of 5.800 EUR. The stock has fluctuated within a day range of 1.890 EUR to 1.895 EUR, while its 52-week range spans from 1.410 EUR to 2.900 EUR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.